Supernus Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SUPN research report →
About the company
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention.
- CEO
- Jack A. Khattar
- IPO
- 2012
- Employees
- 674
- HQ
- Rockville, MD, US
Price Chart
- Market Cap
- $2.79B
- P/E
- -93.96
- P/S
- 3.59
- P/B
- 2.57
- EV/EBITDA
- 51.11
- Div Yield
- 0.00%
- Gross Margin
- 89.42%
- Op Margin
- -5.37%
- Net Margin
- -3.74%
- ROE
- -2.73%
- ROIC
- -2.16%
- Revenue
- $718.95M · 8.63%
- Net Income
- $-38,550,000 · -152.19%
- EPS
- $-0.68 · -150.75%
- Op Income
- $-36,864,000
- FCF YoY
- -73.14%
- 52W High
- $59.68
- 52W Low
- $31.35
- 50D MA
- $47.30
- 200D MA
- $49.01
- Beta
- 0.54
- Avg Volume
- 715.37K
Get TickerSpark's AI analysis on SUPN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 16, 26 | Bhatt Padmanabh P. | other | 5,000 |
| Mar 17, 26 | Bhatt Padmanabh P. | other | 15,000 |
| Mar 16, 26 | Bhatt Padmanabh P. | other | 18,000 |
| Mar 17, 26 | Bhatt Padmanabh P. | other | 12,250 |
| Mar 16, 26 | Bhatt Padmanabh P. | other | 4,250 |
| Mar 16, 26 | Bhatt Padmanabh P. | other | 22,750 |
| Mar 17, 26 | Bhatt Padmanabh P. | other | 22,750 |
| Mar 17, 26 | Bhatt Padmanabh P. | sell | 27,710 |
| Mar 16, 26 | Bhatt Padmanabh P. | sell | 34,114 |
| Mar 18, 26 | Bhatt Padmanabh P. | other | 7,250 |
Our SUPN coverage
Recent articles, reports, and earnings notes.
No research on SUPN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SUPN report →Similar companies
Peers in the same neighborhood.